Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical ...

In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...

ET Net News Agency, 12 August 2025] CSPC PHARMA (01093) fell 2.8% to HK$10.07. It hits an intra-day low of HK$10.02, and an intra-day high of HK$10.46. The total shares traded was 83.88 million, with ...

Goldstream Investment Ltd. (1328.HK) has emerged as one of the shiniest stocks in that group, experiencing massive gains amid ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

The cancer cachexia therapeutics market is gaining traction due to the rising global cancer burden and high prevalence of cachexia in advanced-stage patients. With limited approved treatments, there’s ...

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...